SummitTX Capital L.P. Buys 152,049 Shares of Eupraxia Pharmaceuticals Inc. $EPRX

SummitTX Capital L.P. raised its stake in Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) by 86.4% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 327,997 shares of the company’s stock after purchasing an additional 152,049 shares during the period. SummitTX Capital L.P. owned 0.54% of Eupraxia Pharmaceuticals worth $2,375,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of EPRX. Integrated Wealth Concepts LLC acquired a new stake in shares of Eupraxia Pharmaceuticals during the 3rd quarter worth about $71,000. Bank of America Corp DE grew its stake in Eupraxia Pharmaceuticals by 402.4% in the 2nd quarter. Bank of America Corp DE now owns 12,559 shares of the company’s stock valued at $72,000 after buying an additional 10,059 shares during the last quarter. Guardian Wealth Advisors LLC NC bought a new position in Eupraxia Pharmaceuticals in the 4th quarter valued at about $76,000. Aptus Capital Advisors LLC bought a new position in Eupraxia Pharmaceuticals in the 4th quarter valued at about $76,000. Finally, Geode Capital Management LLC acquired a new stake in Eupraxia Pharmaceuticals during the fourth quarter worth approximately $105,000.

Eupraxia Pharmaceuticals Price Performance

Shares of Eupraxia Pharmaceuticals stock opened at $6.10 on Wednesday. Eupraxia Pharmaceuticals Inc. has a twelve month low of $5.04 and a twelve month high of $9.32. The company has a quick ratio of 19.31, a current ratio of 19.31 and a debt-to-equity ratio of 0.02. The company has a 50-day simple moving average of $6.50 and a two-hundred day simple moving average of $7.33. The stock has a market capitalization of $396.62 million, a price-to-earnings ratio of -5.81 and a beta of 1.05.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.01). Analysts forecast that Eupraxia Pharmaceuticals Inc. will post -0.88 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on EPRX shares. Zacks Research upgraded Eupraxia Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Thursday, May 7th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Eupraxia Pharmaceuticals in a research note on Wednesday, July 15th. Wall Street Zen cut Eupraxia Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday, May 16th. Oppenheimer assumed coverage on Eupraxia Pharmaceuticals in a research note on Thursday, June 25th. They issued an “outperform” rating and a $17.00 price target for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a report on Friday, July 17th. Two analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $18.00.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.